Global Viral Vectors And Plasmid Dna Market 2024 , Forecast To 2033
7 Mar, 2024
The viral vectors and plasmid DNA market (10) has witnessed rapid growth, rising from $1.05 billion in 2023 to $1.2 billion in 2024 at a CAGR of 14.8%, driven by increasing prevalence of cancer and growing awareness of gene therapy. Looking forward, the market is projected to continue growing, reaching $1.66 billion in 2028 at a CAGR of 8.4%, fueled by emerging therapeutic applications and increased funding, with major trends including advances in manufacturing technology and safety standards.
Global Viral Vectors And Plasmid DNA Market Key Driver
The rise in the global incidence of cancer is driving the viral vector and plasmid DNA market (21). The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits (22). For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US (23). The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases (24). The rise in the global incidence of cancer is expected to boost the demand for the viral vectors and plasmid DNA market over the coming years (25).
Get A Free Sample Of The Global Viral Vectors And Plasmid DNA Market ReportGlobal Viral Vectors And Plasmid DNA Market Segments
The viral vectors and plasmid dna market covered in this report is segmented –
1) By Product: Plasmid DNA, Viral Vectors
2) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Other Diseases
3) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications
4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies
By Geography: The countries covered in the viral vectors and plasmid dna market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the viral vectors and plasmid DNA market in 2023. The Middle East is expected to be the fastest growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the viral vectors and plasmid dna market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Major Viral Vectors And Plasmid DNA Industry Players
FUJIFILM Diosynth Biotechnologies; FinVector Vision Therapies; Lonza Group AG; Cobra Biologics and Pharmaceutical Services; Brammer Bio; ??n?k? ??r??r?t??n; Cell and Gene Therapy Catapult; VGXI Inc.; MassBiologics; Sanofi; Spark Therapeutics; UniQure NV; Thermo Fisher Scientific; VIROVEK; SIRION Biotech GmbH; ALDEVRON; Oxford BioMedica; PlasmidFactory GmbH & Co. KG; Biovian Oy; BioReliance Corporation; 4D Molecular Therapeutics; Renova Therapeutics; Shenzhen SiBiono GeneTech Co.; Vigene Biosciences Inc.; Novasep; Genzyme Corporation; Oxford Gene Technology; Richter-Helm; ??l?n NV; MolMed; Merck KGaA Inc.; Catalent Inc.; WuXi AppTec; GenScript Biotech Corporation; Eurogentec; Creative Biogene
Get The Full Global Viral Vectors And Plasmid DNA Market Report
Viral Vectors And Plasmid DNA Market Overview
Viral vectors refer to a tool made of a viral genome that has been converted into a plasmid-based technology, modified for safety by deleting several necessary genes, and the viral components have been separated. Whereas, Plasmid DNA refers to a tiny, circular DNA molecule that can be found in some bacteria and other tiny organisms. Physically distinct from chromosomal DNA, plasmids multiply on their own.